Good news, STLT 10-Q is out. Awesome Venodol gross profit margin, but the revenue is pathetic so far, even seems to be down. They need to find a way to ramp up sales. The product is awesome and could be a huge winner.
Insiders/CEO seem to be paying the bills with loans, K4. Convertible debt conversion so far seems to have been 25/30 cents and higher and not much volume. Still looks like a bargain.
All of my posts are strictly opinions and should not be considered to be facts, or investment advise. They are for entertainment purposes only.